These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 26168222)

  • 21. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
    Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
    Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
    Blaney JE; Marzi A; Willet M; Papaneri AB; Wirblich C; Feldmann F; Holbrook M; Jahrling P; Feldmann H; Schnell MJ
    PLoS Pathog; 2013; 9(5):e1003389. PubMed ID: 23737747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.
    Bounds CE; Kwilas SA; Kuehne AI; Brannan JM; Bakken RR; Dye JM; Hooper JW; Dupuy LC; Ellefsen B; Hannaman D; Wu H; Jiao JA; Sullivan EJ; Schmaljohn CS
    PLoS One; 2015; 10(9):e0137786. PubMed ID: 26422247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.
    Wong G; Richardson JS; Pillet S; Racine T; Patel A; Soule G; Ennis J; Turner J; Qiu X; Kobinger GP
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S379-83. PubMed ID: 25957963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates.
    Pyankov OV; Bodnev SA; Pyankova OG; Solodkyi VV; Pyankov SA; Setoh YX; Volchkova VA; Suhrbier A; Volchkov VV; Agafonov AA; Khromykh AA
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S368-71. PubMed ID: 25732811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.
    Warfield KL; Swenson DL; Olinger GG; Kalina WV; Aman MJ; Bavari S
    J Infect Dis; 2007 Nov; 196 Suppl 2():S430-7. PubMed ID: 17940980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.
    Konduru K; Bradfute SB; Jacques J; Manangeeswaran M; Nakamura S; Morshed S; Wood SC; Bavari S; Kaplan GG
    Vaccine; 2011 Apr; 29(16):2968-77. PubMed ID: 21329775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open-label phase I clinical trial of Ad5-EBOV in Africans in China.
    Wu L; Zhang Z; Gao H; Li Y; Hou L; Yao H; Wu S; Liu J; Wang L; Zhai Y; Ou H; Lin M; Wu X; Liu J; Lang G; Xin Q; Wu G; Luo L; Liu P; Shentu J; Wu N; Sheng J; Qiu Y; Chen W; Li L
    Hum Vaccin Immunother; 2017 Sep; 13(9):2078-2085. PubMed ID: 28708962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.
    Olinger GG; Bailey MA; Dye JM; Bakken R; Kuehne A; Kondig J; Wilson J; Hogan RJ; Hart MK
    J Virol; 2005 Nov; 79(22):14189-96. PubMed ID: 16254354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful topical respiratory tract immunization of primates against Ebola virus.
    Bukreyev A; Rollin PE; Tate MK; Yang L; Zaki SR; Shieh WJ; Murphy BR; Collins PL; Sanchez A
    J Virol; 2007 Jun; 81(12):6379-88. PubMed ID: 17428868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease.
    Wang H; Wong G; Zhu W; He S; Zhao Y; Yan F; Rahim MN; Bi Y; Zhang Z; Cheng K; Jin H; Cao Z; Zheng X; Gai W; Bai J; Chen W; Zou Y; Gao Y; Gao GF; Yang S; Xia X; Qiu X
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.
    Bukreyev A; Marzi A; Feldmann F; Zhang L; Yang L; Ward JM; Dorward DW; Pickles RJ; Murphy BR; Feldmann H; Collins PL
    Virology; 2009 Jan; 383(2):348-61. PubMed ID: 19010509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.
    Wong G; Richardson JS; Cutts T; Qiu X; Kobinger GP
    Antiviral Res; 2015 Apr; 116():17-9. PubMed ID: 25596432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.
    Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R
    Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.
    Dolzhikova IV; Zubkova OV; Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Tokarskaya EA; Simakova YV; Egorova DA; Scherbinin DN; Tutykhina IL; Lysenko AA; Kostarnoy AV; Gancheva PG; Ozharovskaya TA; Belugin BV; Kolobukhina LV; Pantyukhov VB; Syromyatnikova SI; Shatokhina IV; Sizikova TV; Rumyantseva IG; Andrus AF; Boyarskaya NV; Voytyuk AN; Babira VF; Volchikhina SV; Kutaev DA; Bel'skih AN; Zhdanov KV; Zakharenko SM; Borisevich SV; Logunov DY; Naroditsky BS; Gintsburg AL
    Hum Vaccin Immunother; 2017 Mar; 13(3):613-620. PubMed ID: 28152326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.